This study was a double-blind, randomized, placebo-controlled, clinical trial with two parallel groups. Participants reported to a single investigational center in Ohio (i.e., The Center for Applied Health Sciences) during the 12 week trial.
This study was a double-blind, randomized, two-arm, placebo-controlled trial of apparently healthy men and women recruited at a single investigational center in Northeast Ohio (i.e. The Center for Applied Health Sciences). Subjects will attend four study visits. During Visit 1, subjects will be screened for participation (i.e., medical history, physical exam, routine blood work \[also HgA1c, insulin\], background baseline diet). Over the next 12 weeks, subjects will attend Visits 2-4, wherein assessments of serum glucose, insulin, HOMA-IR, 2-hour glucose tolerance test (GTT), NMR profile, HgA1c, C-reactive protein, adiponectin, ferritin, waist circumference, quality of life questionnaire, and various visual analog scales for appetite, satiety, and cravings will be made (see Study Schematic for details). Comprehensive side effect profile/ adverse event monitoring will take place throughout the study duration. The study will be conducted following ICH-GCP guidelines to ensure subject safety and scientific integrity of the data.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Enrollment
26
The Center for Applied Health Sciences
Canfield, Ohio, United States
Glucose kinetics
Serum glucose response during a two hour oral sucrose tolerance test.
Time frame: Change from baseline to 12 weeks.
Insulin kinetics
Serum insulin response during a two hour oral sucrose tolerance test.
Time frame: Change from baseline to 12 weeks.
Hemoglobin A1c (HgA1c)
Serum HgA1c
Time frame: Change from baseline to 12 weeks.
C-reactive protein
Serum C-reactive protein
Time frame: Change from baseline to 12 weeks.
Adiponectin
Serum adiponectin
Time frame: Change from baseline to 12 weeks.
Ferritin
Serum ferritin
Time frame: Change from baseline to 12 weeks.
Appetite
Appetite as measured by a 10 cm visual analogue scale, where higher values represent greater appetite. Values range from 1-10, and a greater appetite score would be a worse outcome in these participants.
Time frame: Change from baseline to 12 weeks.
Satiety
Satiety as measured by a 10 cm visual analogue scale, where higher values represent greater satiety. Values range from 1-10, and a greater satiety score would be a better outcome in these participants.
Time frame: Change from baseline to 12 weeks.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Food cravings
Food cravings as measured by a 10 cm visual analogue scale, where higher values represent greater food cravings. Values range from 1-10, and a greater food cravings score would be a worse outcome in these participants.
Time frame: Change from baseline to 12 weeks.
Sweet food cravings
Sweet food cravings as measured by a 10 cm visual analogue scale, where higher values represent greater sweet food cravings. Values range from 1-10, and a greater sweet food cravings score would be a worse outcome in these participants.
Time frame: Change from baseline to 12 weeks.
Blood urea nitrogen to creatinine ratio
The ratio of blood urea nitrogen to creatinine in serum.
Time frame: Change from baseline to 12 weeks.